Secondary analysis of two trials of gantenerumab in early Alzheimer's disease: treatment was associated with greater brain parenchymal volume loss than placebo, with no difference by ARIA; ARIA was linked to ventricular enlargement offset by less external CSF expansion.
Secondary analysis
Tonietto et al. Volume change with gantenerumab: Impact of amyloid-related imaging abnormalities and amyloid removal